Newsroom

MALVERN, Penn. — Feb. 28, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company developing drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to lead candidate GC4419, a highly selective and potent small molecule dismutase mimetic, for the … Continued

MALVERN, PA, December 18, 2017 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. today reported positive results from its Phase 2b clinical trial for its lead drug candidate, GC4419 for severe oral mucositis (SOM) in patients with head and neck cancer receiving chemoradiation. In the intent-to-treat population, the 90 milligram (mg) dose of GC4419 met its primary … Continued

MALVERN, PA, July 31, 2017 — Galera Therapeutics, Inc., a clinical stage biotechnology company announced today that GC4419 has received a Promising Innovative Medicines (PIM) designation in the United Kingdom (UK) by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the reduction of the duration or incidence of radiation and chemotherapy induced severe oral … Continued

MALVERN, PA, June 15, 2017 — Galera Therapeutics, Inc. announced today that it has completed enrollment in its phase 2b clinical trial evaluating the efficacy, safety and tolerability of GC4419 as a treatment for reducing the incidence and duration of oral mucositis (OM) in head and neck cancer patients receiving chemoradiation therapy. GC4419 is a … Continued

MALVERN, PENNSYLVANIA – November 28, 2016– Galera Therapeutics, Inc., a clinical-stage biotechnology company developing transformational new treatments for cancer patients, announced today it has received $15 million in funding from new investor Sofinnova Ventures, bringing its Series B financing total to $57 million. Sofinnova joins existing investors New Enterprise Associates, Novartis Venture Fund, Novo Ventures, … Continued

MALVERN, PA – September 27, 2016 – Galera Therapeutics, Inc., a clinical-stage biotechnology company developing new treatments for cancer patients, today announced the presentation of final data, including one-year tumor control, from a Phase 1b/2a clinical trial of GC4419, an investigational drug candidate for the reduction of severe chemoradiation-induced oral mucositis (OM), in an oral … Continued

MALVERN, PA – June 6, 2016 – Galera Therapeutics, Inc., a clinical-stage biotechnology company developing new treatments for cancer patients, today announced the presentation of data from a Phase 1b/2a clinical trial of GC4419, an investigational drug candidate for the reduction of chemoradiotherapy-induced oral mucositis (OM), at the American Society of Clinical Oncology (ASCO) Annual … Continued

MALVERN, PA – February 3, 2016 – Galera Therapeutics, Inc., a clinical-stage biotech developing new treatments for cancer patients, announced today it has received an additional $5 million in funding from Enso Ventures to bring its Series B financing total to $42 million. Enso Ventures joins existing investors New Enterprise Associates, Novartis Venture Fund, Novo … Continued

MALVERN, PA – January 7, 2016 – Galera Therapeutics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for GC4419, an investigational drug candidate, for the reduction of severity and incidence of radiation and chemotherapy induced oral mucositis (OM). Galera also announced today that it has begun enrolling … Continued

MALVERN, PA – October 14, 2015 – Galera Therapeutics, Inc., a clinical-stage biotech developing new treatments for cancer patients, announced today it has completed a $37 million Series B financing. The proceeds of the financing will be used to advance the development of Galera’s selective dismutase mimetics, including progressing lead candidate GC4419 into a Phase … Continued